The past week was busy for the biotech sector with pipeline updates for most biotech bigwigs. While Amgen AMGN received an FDA nod for its osteoporosis drug, Gilead Sciences, Inc. GILD has submitted an application for the label expansion of its HIV drug, Descovy. Celgene Corporation CELG too has filed a Biologics License Application (BLA) for its pipeline candidate, luspatercept, to the FDA. Meanwhile, Regeneron Pharmaceuticals, Inc. REGN has extended its collaboration agreement with Alnylam. Recap of the Week's Top Stories : FDA Approves Amgen's Osteoporosis Drug Evenity : Amgen and partner UCB announced that the FDA has approved osteoporosis drug, Evenity, for the treatment of osteoporosis in postmenopausal women at high risk for fracture. The FDA approval was based on the results of two phase III studies, namely FRAME and ARCH.